Pancreatic Cancer Action Network

Each year, the PanCAN Scientific Summit brings together some of the brightest minds in pancreatic cancer research: © stock.adobe.com.

Each year, the PanCAN Scientific Summit brings together some of the brightest minds in pancreatic cancer research — scientists, clinicians, industry partners, and advocates — all driven by a shared mission, to improve outcomes and bring hope to patients and families. This year’s Summit was more than just a meeting of experts; it was a celebration of collaboration, innovation, and progress. The energy in the room was unmistakable, fueled by a deep commitment to push the science forward, even as federal research funding faces uncertainty.

Throughout the event, participants shared the latest findings across the pancreatic cancer landscape from early detection strategies and biomarker discoveries to promising advances in immunotherapy and KRAS-targeted treatments. Attendees also explored how emerging tools like artificial intelligence and big data are opening new doors to understanding pancreatic tumors and identifying which patients might benefit most from certain therapies.

Following the Summit, members of the PanCAN team joined colleagues from around the world at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer. This gathering expanded the global conversation, spotlighting cutting-edge work from academic and industry leaders alike. Presentations covered key themes such as overcoming treatment resistance, understanding the tumor microenvironment, and finding new ways to detect pancreatic cancer earlier, when it’s most treatable.

Together, these two events underscored a powerful truth: progress in pancreatic cancer happens when collaboration meets purpose. The dedication of researchers, clinicians, and advocates around the world continues to move the field forward, one discovery, one partnership, one patient at a time.

To explore the scientific highlights and key takeaways from both meetings, read the latest 

 from Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer: 

https://pancan.org/news/research-spotlight/research-spotlight-building-momentum-and-hope-reflections-on-pancans-2025-scientific-summit-and-aacr-pancreatic-cancer-conference/

Articles

The PanCAN Scientific Summit and AACR Special Conference on Pancreatic Cancer brought together experts to advance pancreatic cancer research. The events highlighted collaboration, innovation, and progress in areas such as early detection, biomarker discoveries, immunotherapy, and KRAS-targeted treatments. Emerging technologies like artificial intelligence and big data were discussed for their potential to enhance understanding and treatment of pancreatic tumors. The conferences emphasized the importance of global collaboration in overcoming treatment resistance, understanding the tumor microenvironment, and improving early detection, ultimately driving progress in pancreatic cancer research.

Each year, the PanCAN Scientific Summit brings together some of the brightest minds in pancreatic cancer research.

Uniting for Progress: Highlights from the PanCAN Scientific Summit and AACR Pancreatic Cancer Conference 

Artificial intelligence (AI) is revolutionizing the way cancer is studied and treated: © stock.adobe.com.

Artificial intelligence (AI) is revolutionizing the way cancer is studied and treated. At PanCAN, we’re combining AI with our 

 platform, a secure, centralized system that integrates diverse health data contributed by patients through programs like 

SPARK houses clinical information, genetic and molecular data, tumor images, and even patient-reported outcomes, all de-identified and structured for scientific use. By analyzing these large, complex datasets, AI enables researchers to uncover patterns and insights more quickly, helping advance early detection, personalize therapies, and identify new avenues for treatment.

In this month’s Research Spotlight, PanCAN’s Chief Scientific and Medical Officer, 

, to explore how SPARK and AI are driving discoveries in collaboration with academic and industry partners. These efforts are helping advance early detection, improve drug development, and create new tools that bring research insights closer to patients.

AI applications range from improving clinical trial design and streamlining drug development to analyzing imaging and pathology data for potential therapeutic insights. These collaborations are accelerating the translation of research findings from the lab to the clinic, bringing tangible benefits to patients faster than ever before. What makes SPARK especially transformative is its ability to unify information that was once siloed. By integrating genetic profiles, clinical records, pathology slides, and more, researchers can connect the dots in ways that were previously impossible. AI allows these massive datasets to be processed efficiently, revealing hidden insights that can guide research decisions and inform patient care. This collaborative ecosystem ensures that every contribution from patients and families drives meaningful progress in pancreatic cancer research.

Looking ahead, PanCAN plans to incorporate even more data from ongoing clinical trials into SPARK. This expansion will provide researchers with an even richer, more detailed picture of the disease, enabling new discoveries and fostering innovations in treatment, prevention, and early detection. By harnessing AI, SPARK, and the collective efforts of patients, families, and partners, PanCAN is creating powerful tools that bring hope and advance better outcomes for everyone affected by pancreatic cancer.

Read the full September Research Spotlight to learn more: 

https://pancan.org/news/research-spotlight-qa-with-pancans-chief-business-officer-sudheer-doss-phd/

Artificial intelligence is transforming cancer research and treatment by integrating with PanCAN's SPARK platform, which consolidates diverse health data. This system includes clinical, genetic, molecular, and patient-reported information, enabling AI to analyze complex datasets for early detection, personalized therapies, and new treatment avenues. Collaborations with academic and industry partners enhance drug development and clinical trial design. SPARK's ability to unify previously siloed data accelerates research translation to clinical applications. Future expansions will incorporate more clinical trial data, fostering innovations in pancreatic cancer treatment and prevention.

Artificial intelligence (AI) is revolutionizing the way cancer is studied and treated. 

Harnessing AI and Patient Data to Transform Pancreatic Cancer Research

Research Spotlight by Dr. Anna Berkenblit

Pancreatic cancer remains one of the deadliest cancers because it is often detected at an advanced stage when treatment options are limited. PanCAN launched its 

 (EDI) to investigate whether a rise in blood sugar, in combination with other clinical signs, could serve as an early indicator of the disease.

Building on previous research, EDI aims to determine whether identifying and closely monitoring patients with newly elevated blood sugar and weight loss and utilizing the ENDPAC (Enriching New-onset Diabetes for Pancreatic Cancer) risk score could lead to earlier diagnosis and, ultimately, better outcomes. The study reached a 

 in January 2025, with full enrollment of more than 8,800 participants, and follow-up analyses are expected to provide deeper insight in the coming years.

, and involving many of the EDI investigators recently confirmed that people with glycemically-defined new-onset diabetes (GNOD) are at increased risk for pancreatic cancer. 

 important differences in risk across racial and ethnic groups.

Together, these efforts represent a bold step toward earlier detection and more equitable outcomes in pancreatic cancer. Recently I had the opportunity to interview my esteemed colleague Lynn Matrisian, PhD, MBA, Chief Science Advisor at PanCAN, who spearheaded EDI from the start. With this Q&A we had the chance to explore the motivation behind the EDI study, the significance of recent findings, and what the future may hold for early detection and screening.

Anna: What was the motivation behind launching PanCAN’s Early Detection Initiative (EDI)?

 The primary motivation was the urgent need to improve pancreatic cancer survival by diagnosing patients earlier. With the currently available treatments, shifting even a portion of diagnoses to earlier stages could significantly improve overall survival. PanCAN recognized that while advancing treatment is vital, early detection efforts must happen in parallel. The EDI was created to explore promising early indicators such as a rise in blood sugar levels, which could signal pancreatic cancer before more common symptoms appear.

Anna: How does the EDI build on previous research, and what role did the ENDPAC score play in its development?

 The EDI builds directly on research led by Dr. Suresh Chari, who discovered that a new rise in blood sugar might signal pancreatic cancer. Initially studied at the Mayo Clinic, this concept evolved through the development of the 

, which combines three clinical factors: age, change in blood sugar, and change in weight.

EDI takes this one step further by applying the ENDPAC score prospectively and offering imaging to a subset of individuals at elevated risk, helping researchers assess whether this model can meaningfully identify cancer earlier.

Anna: That’s fascinating, especially how the EDI builds on the ENDPAC score to enhance early detection. I imagine that testing such models across diverse populations is also crucial. With that in mind, what were some of the most surprising or significant findings from the recent GNOD study, particularly around racial and ethnic differences?

 In addition to confirming that a rise in blood sugar is an early warning sign of pancreatic cancer, one of the most significant findings was that the link between glycemically-defined new-onset diabetes (GNOD) and pancreatic cancer varied by race and ethnicity. While the original Mayo Clinic study population was predominantly white, the recent study included a much more diverse cohort, allowing for new insights.

The data suggested that GNOD was a stronger predictor of pancreatic cancer in non-Hispanic white individuals, while the association was less pronounced in African American, Hispanic, and Asian American/Pacific Islander populations. This finding underscores the importance of studying diverse populations and tailoring early detection strategies accordingly. We are eager to determine whether the additional clinical parameters incorporated into EDI, via the ENDPAC score, help enrich the likelihood of finding pancreatic cancer amongst the participants across racial and ethnic groups.

Anna: In January 2025, PanCAN’s EDI study reached a milestone by fully enrolling more than 8,800 participants. Why is this significant?

 Reaching full enrollment is a critical milestone in research. The scale and diversity of the EDI cohort allows for rigorous, prospective analysis of the ENDPAC model and other related early detection signals. Unlike retrospective studies, which rely on existing data, prospective studies follow participants in real time, offering stronger evidence of cause and effect. This large, well-characterized group will enable researchers to examine, over the next several years, whether early indicators like high blood sugar and weight loss truly lead to earlier diagnosis and ultimately better outcomes.

Anna: What message would you share with PanCAN’s donors and supporters about the impact of their contributions on early detection research?

 Donor support is absolutely vital to making this research possible. Studies like GNOD and EDI are multi-year, resource-intensive efforts that wouldn’t happen without funding. The recent GNOD study has now validated the foundational hypothesis behind EDI, showing a real signal worth pursuing. The upcoming results from EDI will take that one step further. This work brings us closer to a future where high-risk individuals can be flagged through routine testing and potentially diagnosed early, transforming the pancreatic cancer landscape. Thanks to our supporters, we are making real progress toward that goal.

Anna: Thank you, Lynn, for sharing such insightful perspectives and helping us better understand the importance and promise of early detection in pancreatic cancer.

This conversation highlights the incredible progress being made. As we await the results of the EDI in the coming years, it’s clear that this study and the dedicated researchers behind it have laid crucial groundwork for the future of pancreatic cancer detection and care. PanCAN’s unwavering commitment to early detection is reshaping what’s possible in the fight against pancreatic cancer.
Every data point, every enrolled participant, and every donor contribution brings us closer to a future where pancreatic cancer is no longer primarily a late-stage diagnosis. Together, we’re building hope and a roadmap for earlier detection, more personalized care, and better outcomes for all patients.

Stay tuned for future updates as we continue to spotlight the science and stories propelling this mission forward.

Editor’s note: The “Research Spotlight” series is written by

, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and research in pancreatic cancer. Follow Dr. Berkenblit on

Pancreatic cancer is often diagnosed at an advanced stage, limiting treatment options. PanCAN's Early Detection Initiative (EDI) aims to identify early indicators, such as elevated blood sugar, to improve early diagnosis and outcomes. The ENDPAC risk score, which considers age, blood sugar, and weight changes, is central to this effort. The EDI study achieved full enrollment of over 8,800 participants in January 2025, enabling prospective analysis. Recent findings highlight racial and ethnic differences in risk, emphasizing the need for diverse study populations and tailored detection strategies.

Pancreatic cancer remains one of the deadliest cancers because it is often detected at an advanced stage when treatment options are limited.

Research Spotlight by Dr. Anna Berkenblit: Q&A with Lynn Matrisian, PhD, MBA, Chief Science Advisor at PanCAN

Pancreatic cancer is one of the most challenging cancers to treat, often requiring highly complex surgical procedures and advanced molecular insights to guide therapy. From groundbreaking surgical innovations to targeted genetic research, the landscape of pancreatic cancer treatment is shifting toward more personalized, and more hopeful approaches.

One such advancement is the robotic Whipple, a high-tech way to perform one of the most intricate operations in surgical oncology. Paired with an increasing understanding of genetic mutations like KRAS, which play a critical role in pancreatic cancer, these developments are transforming how patients are diagnosed, treated, and supported.

While these advancements are still emerging, they offer a powerful sense of progress and possibility. Access to robotic surgery and precision medicine may still be limited to certain centers and patient populations, but awareness and advocacy can help expand availability. Patients and caregivers equipped with the right information are empowered to ask critical questions, seek out specialists, and explore all available options, including clinical trials and biomarker testing—to make informed decisions about care.

 by PanCAN’s Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, she explores the intersection of surgical innovation and molecular medicine, offering a glimpse into the promising future of pancreatic cancer care.

Pancreatic cancer treatment is evolving with advancements in surgical techniques and molecular insights, leading to more personalized approaches. The robotic Whipple procedure exemplifies surgical innovation, while understanding genetic mutations like KRAS enhances targeted therapies. Although these advancements are not yet universally accessible, they signify progress and potential in pancreatic cancer care. Increased awareness and advocacy are crucial for expanding access to these innovations. Patients and caregivers, informed about options such as clinical trials and biomarker testing, can make empowered decisions regarding their treatment and care.

Pancreatic cancer is one of the most challenging cancers to treat.

Pancreatic Cancer Action Network

Uniting for Progress: Highlights from the PanCAN Scientific Summit and AACR Pancreatic Cancer Conference

Harnessing AI and Patient Data to Transform Pancreatic Cancer Research

Research Spotlight by Dr. Anna Berkenblit: Q&A with Lynn Matrisian, PhD, MBA, Chief Science Advisor at PanCAN

Advances in surgical techniques and targeted therapies for Pancreatic Cancer

Latest News